Activities of antifungal agents against yeasts and filamentous fungi:: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

被引:106
作者
Lass-Floerl, Cornelia [1 ]
Mayr, Astrid [1 ]
Perkhofer, Susanne [1 ]
Hinterberger, Guido [1 ]
Hausdorfer, Johann [1 ]
Speth, Cornelia [1 ]
Fille, Manfred [1 ]
机构
[1] Innsbruck Med Univ, Dept Hyg Microbiol & Social Med, Div Hyg & Med Microbiol, A-6020 Innsbruck, Austria
关键词
D O I
10.1128/AAC.00662-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We compared the activities of antifungal agents against a wide range of yeasts and filamentous fungi. The methodology of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for yeasts and spore-forming molds was applied; and a total of 349 clinical isolates of Candida spp., other yeast species, Aspergillus spp., and nondermatophyte non-Aspergillus spp. were investigated. The average geometric mean (GM) of the MICs of the various drugs for Candida spp. were as follows: amphotericin B (AMB), 0.55 mu g/ml; liposomal amphotericin B (1-AMB); 0.35 mu g/ml; itraconazole (ITC), 0.56 mu g/ml; voriconazole (VRC), 0.45 mu g/ml; posaconazole (POS), 0.44 mu g/ml; and caspofungin (CPF), 0.45 mu g/ml. The data indicated that the majority of Candida spp. were susceptible to the traditional and new antifungal drugs. For Aspergillus spp., the average GM MICs of AMB, 1-AMB, ITC, VRC, POS, and CPF were 1.49 mu g/ml, 1.44 mu g/ml, 0.65 mu g/ml, 0.34 mu g/ml, 0.25 mu g/ml, and 0.32 mu g/ml, respectively. For the various zygomycetes, the average GM MICs of AMB, 1-AMB, ITC, and POS were 1.36 mu g/ml, 1.42 mu g/ml, 4.37 mu g/ml, and 1.65 mu g/ml, respectively. Other yeastlike fungi and molds displayed various patterns of susceptibility. In general, the minimal fungicidal concentrations were 1 to 3 dilutions higher than the corresponding MICs. POS, AMB, and 1-AMB showed activities against a broader range of fungi than ITC, VRC, and CPF did. Emerging pathogens such as Saccharomyces cerevisiae and Fusarium solani were not killed by any drug. In summary, the EUCAST data showed that the in vitro susceptibilities of yeasts and filamentous fungi are variable, that susceptibility occurs among and within various genera and species, and that susceptibility depends on the antifungal drug tested. AMB, 1-AMB, and POS were active against the majority of pathogens, including species that cause rare and difficult-to-treat infections.
引用
收藏
页码:3637 / 3641
页数:5
相关论文
共 44 条
  • [11] Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds
    Espinel-Ingroff, A.
    Fothergill, A.
    Ghannoum, M.
    Manavathu, E.
    Ostrosky-Zeichner, L.
    Pfaller, M. A.
    Rinaldi, M. G.
    Schell, W.
    Walsh, T. J.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (07) : 2180 - 2182
  • [12] Utility of mould susceptibility testing
    Espinel-Ingroff, A
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2003, 16 (06) : 527 - 532
  • [13] Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991)
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) : 403 - 409
  • [14] Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.:: NCCLS Collaborative Study
    Espinel-Ingroff, A
    Fothergill, A
    Peter, J
    Rinaldi, MG
    Walsh, TJ
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (09) : 3204 - 3208
  • [15] Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study
    Espinel-Ingroff, A
    Chaturvedi, V
    Fothergill, A
    Rinaldi, MG
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) : 3776 - 3781
  • [16] Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
    EspinelIngroff, A
    Bartlett, M
    Bowden, R
    Chin, NX
    Cooper, C
    Fothergill, A
    McGinnis, MR
    Menezes, P
    Messer, SA
    Nelson, PW
    Odds, FC
    Pasarell, L
    Peter, J
    Pfaller, MA
    Rex, JH
    Rinaldi, MG
    Shankland, GS
    Walsh, TJ
    Weitzman, I
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) : 139 - 143
  • [17] The changing face of fungal infections in health care settings
    Fridkin, SK
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (10) : 1455 - 1460
  • [18] DISSEMINATED ASPERGILLUS-TERREUS INFECTION IN IMMUNOCOMPROMISED HOSTS
    HARA, KS
    RYU, JH
    LIE, JT
    ROBERTS, GD
    [J]. MAYO CLINIC PROCEEDINGS, 1989, 64 (07) : 770 - 775
  • [19] Caspofungin: the first in a new class of antifungal agents
    Kartsonis, NA
    Nielsen, J
    Douglas, CM
    [J]. DRUG RESISTANCE UPDATES, 2003, 6 (04) : 197 - 218
  • [20] Antifungal drug resistance of pathogenic fungi
    Kontoyiannis, DP
    Lewis, RE
    [J]. LANCET, 2002, 359 (9312) : 1135 - 1144